INSMED (INSM) Q4 2025 earnings call transcript

Transcript, summary, guidance, and what analysts pressed on from the INSMED Inc. call on February 19, 2026.

FreeSee INSMED's financials in GloomOpen in browser →Jump to the transcript
Held
February 19, 2026
Length
41 min
Tone
Confident0.88
Analysts
13
Words
6,600
Month 13 culture conversion
82.4% vs 55.6%p-value less than 0.001
Month 15 durable conversion
76.2% vs 47.6%three months off treatment
Month 13 RSS improvement
17.77 vs 14.66 pointsdifference 3.11; p-value 0.0299
Arikayce discontinuation
18.3%22.9% in ARISE
Expanded addressable patients
more than 200,000from around 30,000 today
FDA and PMDA submissions
second half of this year
Expected launch
2027assuming U.S. and Japan approvals

Summary

Management framed Encore as evidence for moving Arikayce into first-line MAC treatment, emphasizing symptom benefit, durable conversion, and a path to broader approval.

  • 82.4%82.4% culture conversion at month 13 and 76.2% durable conversion at month 15 underscored the call’s emphasis on sustained microbiological benefit.
  • 18.3%18.3% treatment discontinuation was lower than in prior studies, despite Encore’s longer treatment period.
  • Management said it would file with FDA and PMDA in the second half, while deferring uptake and peak-sales estimates pending physician research.

Guidance

  • FDA and PMDA submissions are expected in the second half of this year.
  • U.S. and Japan approvals and launch are anticipated in 2027, assuming approval.
  • Addressable patients could expand from around 30,000 to more than 200,000 with an expanded label.
  • This year’s growth-to-net guidance remains low to mid-20s.

What analysts pressed on

  • 01Standard of care: management called Arikayce plus a two-drug regimen a potential new standard and argued rifampin is often omitted or stopped.
  • 02Long-term outcomes: management said no survival-benefit study has been done and framed survival as a question for future work.
  • 03Tolerability: management attributed lower discontinuation to greater physician experience, patient preparation, and earlier treatment; real-world rates were not quantified.
  • 04Treatment duration: management said 12 months produced durable results but left duration to physician discretion.
  • 05Commercial uptake: management said it needs physician research before quantifying uptake, revenue trajectories, or peak sales.
  • 06Regulatory and guidelines: management expects filings in the second half and said guideline decisions are independent of the company.

Notable disclosures

  • 18.3%18.3% Arikayce discontinuation compared with 22.9% in ARISE, despite twice the treatment duration.
  • Management argued the active control’s conversion rates were consistent with ARISE and that the treatment difference came from strong Arikayce-arm results.
  • Management said the study could support conversion of U.S. conditional approval to traditional approval as well as label expansion.

Risks raised

  • No specific study has assessed whether culture conversion translates into a survival benefit.
  • Management has not quantified expected uptake, peak sales, or the pace of adoption in the expanded population.
  • Dysphonia occurred in 50.7% of Arikayce patients versus 8.5% of controls, alongside cough and other respiratory side effects.
  • Regulatory approval and timing remain prospective; management expects filings in the second half and launch in 2027, assuming approvals.

Tone: Confident 0.88

Management expressed strong confidence in the positive efficacy and tolerability profile and rapid regulatory progress, while acknowledging uptake remains unquantified.

Who spoke

Company

  • William LewisChief Executive Officer
  • Martina FlammerChief Medical Officer
  • Kevin MangeChief Development Officer
  • Bryan DunnInvestor Relations

Analysts

  • Greg StuvanovichAnalyst, Mizuho
  • Alina Jason ZamaskiAnalyst, Bank of America
  • Ritu BaralAnalyst, TD Cowen
  • Unidentified AnalystAnalyst
  • Joe SchwartzAnalyst, Leerink Partners
  • Milde DevonAnalyst, Guggenheim Partners
  • Ellie MerleAnalyst, Berkeley
  • Maxwell ScoreAnalyst, Morgan Stanley
  • Matt PhippsAnalyst, William Blair
  • Ash VermaAnalyst, UBS
  • Leonid TimishofAnalyst, RBC Capital Markets
  • Faisal KurshetAnalyst, Jefferies
  • AlexAnalyst, Truist Securities

Full transcript

Analyst questions are marked with a bar. Timestamps are into the recording.

Prepared remarks

00:00

Thank you for standing by and welcome to the InsMed Phase 3B Encore study of error case in patients with newly diagnosed MAC lung infection, not yet treated with antibiotics conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you'd like to withdraw your question, again, press star one. Thank you. I'd now like to turn the call over to Brian Dunn, head of investor relations. You may begin.

00:34

Bryan DunnInvestor Relations

Thank you, Rob. Good day, everyone, and welcome to today's conference call to discuss the top-line results of the Phase 3 Encore study of error case in patients with newly diagnosed or recurrent MAC lung disease who have not started antibiotics. I am joined today by Will Lewis, Chair and Chief Executive Officer, and Martina Flammer, Chief Medical Officer. The call will begin with opening remarks from Will before turning it over to Martina to walk us through the results.

After the prepared remarks, the presenters will be joined by Kevin Mange, Chief Development Officer, and Sarah Bondstein, Chief Financial Officer for the Q&A session.

Before we start, please note that today's call may include forward-looking statements based on our current expectations. These statements represent our judgment as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the results discussed. Please refer to our filings with the Securities and Exchange Commission for more information. As a reminder, the information on today's call is for the benefit of the investment community.

It is not intended for promotional purposes, nor is it sufficient for prescribing decisions. And now, let me turn the call over to Will.

01:34

William LewisChief Executive Officer

Thank you, Brian, and good morning, everyone. We are extremely excited to share with you that the Encore trial was a clear success. On the primary endpoint of change in respiratory symptom score from baseline to month 13, we saw a statistically significant improvement in patients treated with error case on top of multi-drug therapy versus the active comparator arm consisting of placebo plus multi-drug therapy.

On the equally important culture conversion endpoints, we were very pleased to see earlier, greater, and more durable impacts on culture conversion throughout the study, demonstrating highly statistically significant benefits for the error case arm. This result is particularly impressive as it was being compared to an active comparator arm similar to what a patient might receive as first-line treatment in current practice and demonstrates the potential benefit of using error case earlier in the treatment paradigm.

As we celebrate this moment with our investigators and the patient community, it is worth remembering the road that brought us here. As part of our development program, consisting of the Arise and Encore trials, we validated a patient-reported outcome tool for this disease state, a first-of-its-kind, which can be used for future development work in this space.

While other promising treatment candidates have fallen short, error case has consistently shown in each study ever conducted that it is demonstrably effective at clearing Mac bacteria from patient's lungs. Now, based on today's result, we can also say that it may help patients find relief from respiratory symptoms after treatment. We are particularly excited to see a lower discontinuation rate in this trial than we have seen in any past study of error case and no new or unexpected safety signals in the trial.

With this successful readout, we will look to move quickly to pursue regulatory submissions with the FDA and PMDA in the second half of this year, which we anticipate will lead to an expanded label to include all patients with a Mac lung infection. If granted, this would bring our addressable patient population from around 30,000 today to more than 200,000. We also expect these results to support the conversion of error cases' current conditional approval in the U. S. to a traditional approval consistent with Europe and Japan, given that we have now completed the study intended to fulfill the FDA's post-marketing requirement.

We are ecstatic about what today's news could mean for patients with Mac lung disease. Now let me turn the call over to Martina to walk you through the results in more detail.

03:59

Martina FlammerChief Medical Officer

Thank you, Will, and good morning, everyone. I'm pleased to be with you today to share the top line results from our own course study. I'll begin with a brief review of the trial design. Encore enrolled 425 adult patients with non-cavitary lung disease with a newly diagnosed or recurrent Mac lung infection that had not yet been treated with an antibiotic regimen for their present infection.

These participants were randomized on a one-to-one basis to receive either air case plus acetomycin and a sampitol or an empty liposome plus SIBO plus acetomycin and a sampitol. Treatment was administered once daily over a 12-month period followed by three months of treatment. The primary endpoint in Encore was the change from baseline to month 13 in the eight question respiratory symptoms score, or RSS, which was derived from the nine question QLB respiratory domain questionnaire.

This patient reported outcome tool was previously validated and agreed upon with the FDA. Multiplicity control secondary endpoints in the study included the percentage of patients achieving cost or conversion by month 13, durable cost or conversion at month 15, and cost or conversion by month 12, and month 6 in that order of hierarchy, as well as the change from baseline in the promise fatigue score at month 13.

Safety and tolerability data were also collected throughout the study. On slide nine, we provide the baseline characteristics of the trial by treatment arm. Randomization was stratified based on geographic region and whether a patient had a history of previous neck infections.

As you can see, those characteristics used for stratification as well as age, gender, and race were all relatively well balanced between the error case and active comparator arms. While there was a modestly higher mean baseline RSS in the error case arm, it is important to note that the primary analysis was designed to adjust for any baseline imbalances in RSS, geographic region, and history of neck infections.

Now let's take a look at our primary endpoint of change in RSS at month 13. I'm pleased to report that patients in the error case arm showed a least square mean improvement in score of 17.77 points compared to a mean improvement of 14.66 points in the control arm. This separation of 3.11 points was statistically significant with the p-value of 0.0299.

Interestingly, this symptom benefit continued to expand after month 13, with the difference between arms increasing to 4.8 points at month 15 or three months off treatment, with a nominal p-value of 0.0015. This further highlights the durability of the symptom improvement that can be achieved with treatment with error case.

In addition to the comparison I just described, we also conducted a responder analysis using covariate adjusted cumulative distribution function, or CDS curves, which are shown in this slide. On the horizontal axis, the CDS graph plots a continuous view of respiratory symptom score changes, both positive and negative, with improvement on the left of the zero and deterioration on the right of the zero.

The vertical axis plots the cumulative proportion of patients in each study arm that experience at least that level of respiratory symptom score change.

The purple curve represents patients in the error case arm, and the blue curve represents patients in the comparator arm. A positive change in respiratory symptom score represents an improvement of symptoms from baseline to month 13, and the negative change represents a worsening of symptoms.

Based on our prior work with this PRO tool, we establish a range of thresholds that could be considered a meaningful, within-patient change in RSS score, which is the preferred approach recommended by the PRO experts at the FDA. At the low end of that range is a threshold of 16.67 points, and at the high end is 20.83 points.

Importantly, this graph demonstrates that the error case arm outperforms the control across the range represented by both thresholds. The consistent separation you see on this curve means that regardless of what exact values are selected as the range of meaningful with inpatient change by the FDA, error case used in combination with multi-drug regimen would result in more patients achieving a clinically meaningful improvement in respiratory symptoms.

Turning now to culture conversion, which is often cited by physicians as the most meaningful measure of the efficacy of any drug for the treatment of mac lung disease.

To provide some context for our discussion, culture conversion in the on-course study is defined as having two consecutive months of cultures that remain negative for mac. The definition of durable culture conversion of non-15 requires all cultures to be negative at month 11, 12, 13, and 15. Consistent with the results shown in our past trials of error case in both the refractory and front line settings, all quite demonstrated that a significantly greater proportion of patients in the error case arm achieved culture conversion compared to patients in the active control arm, and this was demonstrated across multiple time points in the study.

Beginning with month 13, or the same time period at which we measure the respiratory symptoms score for the primary end point, we saw that 82.4% of patients in the error case arm achieved conversion compared to 55.6% in the active control arm, a highly statistically significant difference of approximately 27 percentage points with a p-value of less than 0.001.

Perhaps even more striking is that this high rate of culture conversion in the error case arm was maintained over time. On slide 13, you'll find results from the key secondary end point of durable culture conversion at month 15, or three months of treatment. 76.2% of error case patients remained converted, while only 47.6% of patients in the active comparative arm maintained negative culture.

This result reflects the separation of approximately 29 percentage points and the p-value that was less than 0.001. This is a particular notable outcome because durable culture conversion is the most important data point for the Japanese regulatory authority and for many prescivers, both in the US and Japan. The greater durability of treatment we see in Encore is consistent with what we saw in both.

The convert study in refractory patients and the arise study in newly diagnosed patients, where those in error case saw a much higher level of maintained culture conversion measured at three months and one month off treatment respectively.

It is important to note that at any measure time point from the start of treatment through month 15, more patients receiving error case achieved culture conversion compared to dose on the active control arm. In fact, the secondary end points of culture conversion at month 12 and month 6 were also highly statistically significant, with each achieving p-values of less than 0.001.

The error case arm also showed a significant benefit on median time to culture conversion, which was achieved at month 2, or the first possible time point, meaning that cultures were negative at month 1 and 2. The median time to culture conversion in the active comparator arm was achieved at month 3, meaning that cultures were negative at month 2 and 3.

The associated hazard ratio for this measure was 2.03, suggesting that patients treated with error case were roughly twice as likely to achieve earlier culture conversion. The nominal p-value for this comparison was less than 0.001.

It is also notable that the separation you see on this slide was driven by very strong conversion rates in the error case arm, rather than any underperformant in the control arm, which demonstrated similar conversion rates as we saw for the control arm in the arrived study and which might be expected for a macro light-based treatment regimen in the real world.

Finally, I want to briefly discuss the safety results from the encore trial. The tolerability profile for error case in combination with multi-drug therapy in encore was consistent with the known profiles of this antibiotic treatment. No new safety events were observed in the error case treatment group and safety in general was as expected in both the error case arm and the control arm.

The error case treatment discontinuation rate observed in this trial was 18.3%, which compares very favorably to the 34.8% rate that we saw in the Conrad study in refractory Mac patients and to the 22.9% rate we saw in the arrived study. The improvement compared to arrived is particularly notable because the treatment period in encore was twice as long.

The empty liposome control discontinuation rate in the control arm in encore was 11.8%. Importantly, the percentage of patients who completed the study was over 90% for both arms in the trial.

Drilling down a bit further, treatment emergent adverse events were reported by 98.1% of patients in the error case arm and 97.2% of patients in the control arm. Adverse events that occurred at least 10% of patients in the treatment arm and more frequently in the error case arm were dysphonia, cough, fatigue, dyspnea, nausea and headache, all of which are consistent with the known safety profile of error case.

The rate of serious treatment emergent adverse events was 14.1% for the error case arm and 11.3% for the control arm.

In summary, the combination of all the data we have presented today is statistically significant benefit on patient symptom scores. Greater, more rapid and more persistent culture conversion and the consistency of the profile provide clear evidence that treatment with error case and in particular early treatment with error case can lead to improved results for patients with neck lung disease.

I'll now turn it back to Will.

15:33

William LewisChief Executive Officer

Thank you, Martina. Today's results are incredibly exciting for all of us at Insmid, but more importantly for all those who struggle with neck lung infections and for those who provide treatment to and care for those patients. Encore has provided new hope that with the early addition of error case to the treatment paradigm, patients can experience improvement in their respiratory symptoms and have a greater chance to convert sooner and stay converted for longer. We will now work with urgency toward making this important treatment available as an approved treatment option for use in all patients with a neck lung infection.

We want to thank our patients and investigators for their courage and support on this journey, which we hope will result in many more patients benefiting from treatment with error case.

With that operator, I'd like to now open the call to questions. Can we take the first question, please?

Questions and answers

16:21

Thank you. We will now begin the question and answer session. If you'd like to ask a question, please press star 1 in your telephone keypad. We ask that you please let me yourself to one question. You may re-enter the queue for any follow-up questions. Your first question today comes from the line of Greg Stuvanovich from Mizuho. Your line is open.

16:40

Greg StuvanovichAnalyst, Mizuho

Hey, good morning. Thanks for taking my questions and congratulations on this data. Just for context, bigger picture with respect to how to put this data in the context of the current standard of care, so to speak, which is like triple antibiotic regimen, given the study while nicely positive. Can you give a sense of maybe how physicians might look at this data and put it into practice in the real world? Thanks.

17:09

William LewisChief Executive Officer

Sure. Well, one of the most exciting things about this study was when we were originally designing it, we worked closely with the KOL community as to what would be the right way to look at this in the front line setting. And what you see today is very clear evidence that error case, in addition to a true drug regimen, provides real benefit both in symptoms and in culture conversion.

That two drug regimen plus error case sets a new standard of care for how to treat initial patients who are diagnosed with mac lung infection. And that was really the intention behind the study to create a path toward a new standard of care. The drug that is sometimes included later on is refampen. It's always been very controversial as to whether or not there's real benefit from its addition.

And there are known safety effects there that really dissuade a lot of physicians from using it. So it was left out in this case, and we're happy to be able to present these positive results that show it is not only a highly beneficial to add error case, but that really when you look at the baseline or the comparator positive control arm, you don't see any absence of effect or benefit from the removal of refampen. So positive on all fronts.

18:20

Your next question comes from Alina of Jason Zamaski from Bank of America. Your line is open.

18:27

Alina Jason ZamaskiAnalyst, Bank of America

Good morning. Let me echo my congratulations on the data and thank you so much for taking our question. Maybe just a follow-up here, but Will and Martina, especially given the culture conversion data, what sort of long-term benefit is this likely to mean for patients? I mean, is there a potential for a survival benefit, or are we just sort of talking about the benefits associated with the discontinuation of refampen? Thanks so much.

18:53

William LewisChief Executive Officer

Thanks for the question. I think I'll just make a comment and turn it over to Martina. The study is obviously unequivocally positive on all fronts, and we're super excited about that. What it may mean for the longer term, I think can begin to be imagined just by virtue of the experience we've had to date, where the drug has been on the market for eight years now in the United States, and in that context, lots of patients and lots of physicians have seen the benefits from its administration.

We haven't done a specific study to look at things like survival benefit, but those are the kinds of questions that we are certainly going to be curious to engage in and answer, and we're now going to be able to do it from a much larger pool of patients as we move to the all-macked diagnosed population, I don't know, Martina, you want to add.

19:37

Martina FlammerChief Medical Officer

Yeah, what I would add is it just shows you what the durable culture conversion benefit is. So this patient at month 13 has been one month off-drug and at month 15 has been three months off-drug, and the hypothesis here is that sometimes for the control regimen, for two regimens, you may get a negative culture, but you may not get a full clearing of bacteria, and error case appears highly effective in eradicating bacteria, because of its mechanism of being right there in the lung, and that is something that might not be achievable with systemic oral antibiotic.

So if you think about the achievement and the opportunity a patient can get from treating with error case in that regimen, it is something to consider also to prevent the patients potentially become refractory. So treating early here is based on this data evidence that would be helpful for patients.

20:40

Sure. Next question comes from the line of retubarrel from TD-Calen. Your line is open.

20:47

Ritu BaralAnalyst, TD Cowen

Good morning, guys. Let me add my congratulations on this data, especially this culture conversion rate. I do want to focus on safety and tolerability, especially if it relates to if there's a type of first-line patient you're going to target and what it might mean for pricing.

Martina, if you could talk about the dysponia rate and the transients of the dysponia, if patients recovered or if there is any permanent dysponia, and how that may relate to the risk to benefit that first-line patients, basically which first-line patients might be appropriate for it and then the impact on growth to that.

21:36

Unidentified AnalystAnalyst

Good, Martina.

21:38

Martina FlammerChief Medical Officer

Yeah. So dysponia along with cough and are very well-described potential side effects for error case. And we've seen in the study that dysponia rates were slightly higher and they're 50.7% while we see them at 8.5% in the control arm. But what we also know after eight years on the market and experience with error case on both the investigator but also with physicians in general, site has now of course been increased.

We also have educated sites of how do you prepare patients for what potential side effects or respiratory side effects they may experience. And we've also learned that if you put in certain measures, for example, gargling with warm water or taking error case before bedtime is the benefit and can ameliorate the symptoms. So overall, the benefit risk is actually very strong.

This is, or 12 months treatment and patients have, as you see, the discontinuation rates are lower than what we've seen in error case for a rise and certainly for a convert. So I think everybody has learned how can I work best with this drug and I would think even the strengthening of the benefit risk.

22:58

William LewisChief Executive Officer

Thanks, Martina and Ritu on the pricing and GTN question. We had priced originally error case for the broader label, so no change in whack on growth to net. For this year, as you know, we guided low to mid-20s. You will see a natural uptick in growth to net as the small manufacturer sort of bleeding happens for error case more broadly, but we have always done and will continue to do appropriate and targeted contracting. This will be, error case is the only controlled product that is approved and now pending FDA approval will also be that in the broader label.

23:35

Your next question comes from a line of Joe Schwartz from layering partners. Your line is open.

23:42

Joe SchwartzAnalyst, Leerink Partners

Thank you and congratulations on the super outcome. Can you help us understand how representative the Encore trial population is relative to real-world treatment practices for front-line Mac and how that should inform our expectations for these results to translate into market penetration, assuming approval?

24:04

William LewisChief Executive Officer

Thanks for the question. Sorry, couldn't be there today, Joe. Over to you, Kevin.

24:09

Kevin MangeChief Development Officer

Yeah, so thanks for the question. So, it is representative of real-world. The comparator here is a clinically relevant comparator out of the gate and it's the same control group that we used in the ERISE study. And so, as Will had said earlier, often the third antibiotic that's used either right away or subsequently as Rifampen, what, in talking with external experts, when we started this program from the United States is more times than Rifampen get stopped and patients are on the Zithermites and the Thamb et al. So, we do think the study is representative of real-world experience. The control group had activity as would be expected for the conversion range at month 12. And so, I think definitively, this study being the largest study ever done in the disease is a double-blind randomized control superiority study, I think shows very clearly the benefit of adding air case on top of the background range and we're symptomatic improvement and microbiological improvement as well too.

25:12

Your next question comes from a line of the Mildevon from Guggenheim Partners. Your line is open.

25:20

Milde DevonAnalyst, Guggenheim Partners

Great. Thanks for taking the question, congrats as well on the data and maybe building on some of the other questions people have been asking just about sort of putting this in context. How do you think about the duration of therapy or what are you sort of modeling as the average duration, given the positive results we're seeing with the culture conversion, do you think people to stay on a year, plus there's a short duration, just any insights that are really helpful as we think about how to model this out. Thanks.

25:45

William LewisChief Executive Officer

Martini, you want to take that one?

25:48

Martina FlammerChief Medical Officer

Yes. So, what we've seen in this study is the 12-month treatment gives patients not only a higher and an early and a greater achievement of culture conversion, but it also gives the durable culture conversion and being three months of treatment and still seeing how good the effect was on the error case arm, whereas as soon as you see that the treatment stops in the control arm, it goes in the other direction and that goes with the hypothesis that you may have enough control of the bacteria in the control arm to have a negative culture, but not necessarily enough to sustain that and come to an eradication of the bacteria.

And you see that also reflected that patients feel better while they are on treatment, also in the control arm, but as soon as that is stopped, you see a decline in the respiratory symptom score, which is also aligned with what we see in the culture conversion at both months, 13 and 15. It's clear that 12 months produces these kinds of results, and obviously, the up to the physician's discretion, what they want to do, but I don't think there's any doubt that the 12-month treatment here is seen as beneficial and sustained over time.

And that's the most important point, particularly from the market access world, where they want to see that kind of impact and uniquely because we also did the arrived study, we have a sort of snapshot of what a shorter duration of treatment might look like, and the simple answer is both the efficacy and the safety are, at least arguably, better in encore than they are in a rise, so that also paints a very positive picture for the 12 months of duration.

27:38

Your next question comes from a line up, Ellie Merle from Berkeley. Your line is open.

27:44

Ellie MerleAnalyst, Berkeley

Okay guys, thanks for taking my question and congrats on the data. What do you think drove the lower discontinuation rate that you saw in the on-core data versus in the arrived study, and I guess how are you thinking about what the discontinuation rate would be in the real world, thanks.

28:01

William LewisChief Executive Officer

So, discontinuation rate, I think, as Martina commented earlier, is in large part due to people becoming more familiar with how this drug needs to be used, how you prepare the patient for what they can expect, and I think, importantly, increasingly, the ability to express to the patient the benefit they will receive if they remain on therapy. I think it's just a collection of all those things in the experience over time that is slowly but surely improving the adverse event rate that we see reported in this study as compared to a rise and certainly compared to convert. I think that is the most important point of this study, is that all of the data here and from a rise and from convert clearly show that you want to treat earlier in order to avoid the patient becoming refractory.

Once they're refractory, the dropout rate from the drug gets much higher, the difficulty of taking it, the duration, all of those things, you still see clear benefit, and that's why the drug was approved for that population initially, but here we see some unexpected and positive findings that the dropout rate is lower. Remember that we thought it actually could be higher because these patients were less sick, perhaps less willing to tolerate the treatment, and yet that is not the case. It's dramatically lower, almost 15 to 20 percent lower than convert. And that implies to us that at least at some level the severity of the disease and our engagement with the antibiotic are causing some of the side effect profile.

In other words, as you overcome that the presence of the much more established refractory infection, you may produce more side effects as you achieve ultimate culture conversion. Acting earlier lowers the severity of that experience because the infection, at least theoretically, is not as well established. So for all those reasons, I think the discontinuation we see in on core is indicative of what we can expect in the real world, and that's a very positive thing as we move up in the treatment cycle to an earlier stage patient.

29:57

Your next question comes from a line of Maxwell's score from Morgan Stanley. Your line is open.

30:04

Maxwell ScoreAnalyst, Morgan Stanley

Great. Thank you very much for taking my question and congrats on the update. So as you move to convert error cases conditional label to traditional approval, and of course expanding to a broader population, how should we think about any shifts in pair behavior or reimbursement? And could you just talk about the, let's say, cadence of uptake that you expect over the next 12 to 24 months in both the U. S. and Japan?

Thank you.

30:29

William LewisChief Executive Officer

Sure. So I think, as Sarah mentioned earlier, we originally priced this drug for the assumption that we'd be treating all Mac patients. So we don't anticipate a different approach in our discussion with the market access world. And what's important here is that all of the data points in a very positive direction for this earlier use of the drug. I think the symptomatic benefit, the culture conversion benefit, all of these things being aligned makes it really easy discussion from my perspective when it comes to market access.

As for the uptake in the next 12 to 24 months, what I would say about that is we are seeing an expansion in the total addressable market from 30,000 patients to more than 200,000. But we need to develop the target product profile now based on these data from the study and take that out into the market and do some research, which we will now do in earnest to get a better sense of what we think that will result in in terms of uptake and what the ultimate benefit will be. And when you begin to see revenue in 2027, assuming that we get approvals in the U. S. and Japan, as we fully expect to, we'll have more to comment about the direction those revenue growth curves might take.

31:40

Your next question comes from a line of Matt Phipps from William Blair. Your line is open.

31:47

Matt PhippsAnalyst, William Blair

Thanks for my questions. Let me extend my congrats as well. Maybe can you tell us what percentage of barricades patients today use your Enlightened Patients Assistance Program? And again, kind of thinking about moving the front line, how do you expand that program to try to capture those patients and any benefits from any changes in the out of pocket that's after this Medicare? Thank you.

32:08

William LewisChief Executive Officer

Sure. So while we haven't given out the specific percentage, what I can tell you is that if you were to take a high benchmark for what would constitute an attractive rate of getting patients into such a program, we are well above that threshold. And we always have been with this. This is a very all encompassing outreach to patients to help them on their journey through the use of this drug and the hopes that it will be the most effective. We fully anticipate being able to extend that to all MAC lung infection patients. And remember that this is the same backbone architecture that we use not only for air case and the refractory population, but also for Bryn Supri and the Bronch Yectus' population.

And so the resources we need to be addressed as much broader population with air case are already in place and experienced. So we expect this to be a smooth transition and a full expansion with hopefully the same kind of conversion into the program that we've seen to date. And just to comment on the out of pocket, I'll just also remind you that we estimate about 60 of the current air case label, about 60% of the Medicare patients. So they're out of pocket under IRAs for all their medicines, caps of 2000. And then for the commercial payer patients, we have a copay assist.

33:27

Your next question comes from a line of Ash Verma from UBS Financial. Your line is open.

33:34

Ash VermaAnalyst, UBS

Hey guys, thanks for taking questions and congrats on the progress here. So yeah, maybe if you can talk about the timeline for getting the frontline data on the label and would the update be contingent on getting this added to some of the guidelines? Or is it more that the FTF tool opens up the label for the uptake for conditions? Thanks.

33:53

William LewisChief Executive Officer

Sure. So obviously the data once processed by both the US and Japanese regulatory authorities would result in label expansion. And we expect that that will be the case. We've indicated that we'll be filing that by the second half of this year. And we would anticipate that those approvals and our ability to launch would take place in 2027, just so we're clear. And I think that that will be a relatively smooth process. I don't know if anyone wants to add any other comments.

34:23

Martina FlammerChief Medical Officer

I think maybe just on the guidelines just to be clear, a guidelines are usually completed independently by professional organizations and experts. Obviously, we are independent of that. But what you often see is if there is new, especially important data becoming available, there is a consideration of that.

34:41

William LewisChief Executive Officer

And let me just make a comment. You know, this is a particularly difficult disease to treat. Every other company that has come along trying to bring forward a medicine has failed to be able to produce clinical trial results in the double blind study that are adequate for approval. And I think that just highlights the desperate need for this patient population. So a clear and strong win like we have today, I would anticipate would be something that is noticed pretty rapidly by the key opinion leader community that is authoring these guidelines.

35:15

Your next question comes from a line of Leonid Timishof from RBC capital markets. Your line is open.

35:23

Leonid TimishofAnalyst, RBC Capital Markets

Hey guys, congrats on the data. And thanks for taking my question. I wanted to ask also on the opportunity. I guess, you know, there's been significant XUS use of error case. So I guess with the label expansion, you know, I'm trying to understand how you're thinking about the balance between XUS and UX and US revenues, especially given that you guys been somewhat cautious of MFM impact. And then related to that, is there anything you can say on epidemiology and just the trends you're seeing with diagnosis rates or prevalence of infection over time?

35:57

William LewisChief Executive Officer

So thanks for the question. Yeah, we do get a meaningful percentage of revenue from Japan in particular for Mac lung infection in the refractory setting. And that's, it's important to remember that while it's not fully understood what causes the Mac lung infection to develop in particular patients, factors that certainly lean in favor of that are an elderly population, prior history of smoking or lung issues, proximity to water. And when we talk about the island nation of Japan, that's pretty much a perfect description of its population.

So with that in mind, it's not surprising to understand that there are more today, there are more diagnosed Mac patients in Japan than there are in the United States. So the opportunity there is quite significant. There is a price differential there that is evolved over time, but it's, but it is important for people to understand we priced at parity between the US and Japan when we launched on a list basis. So, you know, I think Japan will continue to be an interesting opportunity. There are more Mac patients there than there are in the US. Another feature of their annual checkup is that they include an x-ray as a matter of basic practice. So there's a higher propensity to be able to identify this infection that may be contributing to the higher diagnosis rate.

All of those things collectively suggest that we would expect to continue to see material revenue generator from Japan as the label expansion occurs.

37:23

Unidentified AnalystAnalyst

I'll find one else has in your comments.

37:32

Your next question comes from a line of Faisal Kurshet from Jeffries. Your line is open.

37:38

Faisal KurshetAnalyst, Jefferies

Hey guys, thanks for reading the question. Just one quick one. You kind of commentated or characterized the overall time expansion of being sort of like greater than six times the refractory time in terms of number of patients. Could you characterize like what you, how you think about the peak potential uptake, uptake into this opportunity? Like where do you see this, you know, potentially maxing out from a revenue opportunity perspective, given like the other standards of care. Thank you.

38:03

William LewisChief Executive Officer

Yeah, thanks. I appreciate the question. We're still working on the answer to that question to be candid and we needed the target product profile specifically generated from this study in order to be able to go out and have the dialogue with physicians to see how they interpret the risk reward, how they see it for their patient populations, and what the application might be in the practical setting. I think what is important to note here is that the data from this study is unequivocally positive from the perspective of physicians who are seeking to eradicate evidence of the infection in their patient populations. Moreover, if you just reflect on where convert took us, we saw about a third of patients convert after the convert trial, to a point where they had no evidence of bacterial infection.

In the case of oncorner rise, we're seeing north of 80% of the patients converted by month six. That is a striking improvement compared to what happens if you let a patient become refractory. So there is a powerful motivation in the data to move to treat these patients earlier and the dropout rate going down suggests that actually the treatment burden for the patient is reduced. So that collectively paints a very positive picture for expansion into this broader population, how big, how fast, and what that ultimately means for peak sales. We need to come back to you with specifics on that, but certainly we anticipate moving in a very positive direction.

39:29

Your next question comes from a line of Danielle Brill from Truist Securities. Your line is open.

39:37

AlexAnalyst, Truist Securities

Hey guys, this is Alex on for Danielle. Thanks for taking the question and congrats on the data. Just a detailed checkbox question on the discontinuation rate. Given there was a slight imbalance in the rate of discontinuations between the arm, did you perform any sensitivity analyses to query the potential impact of the imbalance? And if so, were the findings consistent with the top line analyses? Thanks so much.

40:01

William LewisChief Executive Officer

I'll turn that one over to Kevin.

40:01

Kevin MangeChief Development Officer

Yeah, so bottom line is those patients that may have discontinued their treatment and had missing values, they were considered in a pre-specified way in the analysis. So what you're seeing here in the RSS as well as culture results does consider all that and so is a really strong reflection of how robust the study was and insensitive to things like that.

40:26

And there are no further questions. This concludes today's conference call. Thank you for your participation. You may now disconnect.

Other INSMED earnings calls

  • Q3 2026 earnings call

    Management framed the call around Brinsupri’s launch momentum, a larger respiratory growth opportunity, and advancing TPIP and earlier-stage pipeline programs.

    Oct 29, 2026Confident0.82
  • Q2 2026 earnings call

    Management framed the quarter as evidence of launch execution and a broader, increasingly valuable pipeline, while emphasizing durable growth potential and financial discipline.

    Aug 06, 2026Confident0.82
  • Q1 2026 earnings call

    Management framed the launch as stronger than expected, with improving organic demand and execution metrics supporting—but not yet prompting an increase to—full-year guidance.

    May 07, 2026Confident0.78

All INSMED transcripts

About this transcript

The summary, guidance, analyst focus, and tone are automated and should be checked against the call before being relied on. Names and figures can be misheard. Listen to the replay.